Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 May 2;62(5):1730-1732.
doi: 10.1093/rheumatology/keac677.

More to B: the growing evidence to inform targeting B cells in scleroderma

Silvia Laura Bosello  1 , Edward M Vital  2   3 , Francesco Del Galdo  2   3
Affiliations
Editorial

More to B: the growing evidence to inform targeting B cells in scleroderma

Silvia Laura Bosello et al. Rheumatology (Oxford). .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Sakkas LI, Katsiari CG, Daoussis D, Bogdanos DP.. The role of B cells in the pathogenesis of systemic sclerosis: an update. Rheumatology 2023;62:1780–6. - PubMed
    1. Thoreau B, Chaigne B, Mouthon L.. Role of B cell in the pathogenesis of systemic sclerosis. Front Immunol 2022;13:933468. - PMC - PubMed
    1. Bellando-Randone S, Del Galdo F, Lepri G. et al. Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). Lancet Rheumatol 2021;3:e834–43. - PubMed
    1. Clark KEN, Campochiaro C, Csomor E. et al. Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2021;80:1584–93. - PubMed
    1. Mackensen A, Müller F, Mougiakakos D. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 2022;28:2124–32. - PubMed